- Home
- INV vs BIOA Comparison
INV vs BIOA Comparison
Compare INV & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INV
- BIOA
- Stock Information
- Founded
- INV 2015
- BIOA 2015
- Country
- INV United States
- BIOA United States
- Employees
- INV N/A
- BIOA N/A
- Industry
- INV
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- INV
- BIOA Health Care
- Exchange
- INV NYSE
- BIOA Nasdaq
- Market Cap
- INV 173.3M
- BIOA 144.1M
- IPO Year
- INV N/A
- BIOA 2024
- Fundamental
- Price
- INV $4.86
- BIOA $3.94
- Analyst Decision
- INV Strong Buy
- BIOA Hold
- Analyst Count
- INV 2
- BIOA 4
- Target Price
- INV $14.00
- BIOA $5.67
- AVG Volume (30 Days)
- INV 58.5K
- BIOA 207.6K
- Earning Date
- INV 05-15-2025
- BIOA 05-06-2025
- Dividend Yield
- INV N/A
- BIOA N/A
- EPS Growth
- INV N/A
- BIOA N/A
- EPS
- INV N/A
- BIOA N/A
- Revenue
- INV $1,220,000.00
- BIOA $1,451,000.00
- Revenue This Year
- INV $1,336.39
- BIOA N/A
- Revenue Next Year
- INV $204.86
- BIOA N/A
- P/E Ratio
- INV N/A
- BIOA N/A
- Revenue Growth
- INV 18.27
- BIOA N/A
- 52 Week Low
- INV $3.00
- BIOA $2.88
- 52 Week High
- INV $18.75
- BIOA $26.62
- Technical
- Relative Strength Index (RSI)
- INV N/A
- BIOA N/A
- Support Level
- INV N/A
- BIOA N/A
- Resistance Level
- INV N/A
- BIOA N/A
- Average True Range (ATR)
- INV 0.00
- BIOA 0.00
- MACD
- INV 0.00
- BIOA 0.00
- Stochastic Oscillator
- INV 0.00
- BIOA 0.00
About INV INNVENTURE INC
Innventure Inc creates, funds, operates, and rapidly scales companies in strategic collaboration with MNCs. It provides company creation, corporate strategy, technology optimization, operations, commercialization, and funding. Innventure analyzes the market, including proprietary data provided by MNCs, to identify where their well-protected, breakthrough technologies address market needs and have the potential to create $1B+ in new enterprise value.
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.